Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7
Primary Industries
- Drugs
- Antibody
- Biotechnology
- Cancer
- Agriculture Forestry & Fishing
- Crop Production
- Proteins
- Disease
- Vaccine
- Agriculture
- Forestry and Fishing
- Technical Know How
- DNA
- cell therapy
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 56588
7,012,172 VIRUS INDUCED GENE SILENCING IN PLANTS 3/14/2006
7,491,509 SYSTEM FOR EXPRESSION OF GENES IN PLANTS 2/17/2009
7,683,238 PRODUCTION OF PHARMACEUTICALLY ACTIVE PROTEINS IN SPROUTED SEEDLINGS 3/23/2010
7,692,063 PRODUCTION OF FOREIGN NUCLEIC ACIDS AND POLYPEPTIDES IN SPROUT SYSTEMS 4/6/2010
8,058,511 SYSTEM FOR EXPRESSION OF GENES IN PLANTS 11/15/2011
8,148,608 SYSTEMS AND METHODS FOR CLONAL EXPRESSION IN PLANTS 4/3/2012
8,173,408 RECOMBINANT CARRIER MOLECULE FOR EXPRESSION, DELIVERY AND PURIFICATION OF TARGET POLYPEPTIDES 5/8/2012
8,591,909 RECOMBINANT CARRIER MOLECULE FOR EXPRESSION, DELIVERY AND PURIFICATION OF TARGET POLYPEPTIDES 11/26/2013
8,597,942 SYSTEM FOR EXPRESSION OF GENES IN PLANTS 12/3/2013
8,951,791 SYSTEM FOR EXPRESSION OF GENES IN PLANTS 2/10/2015
9,012,199 RECOMBINANT CARRIER MOLECULE FOR EXPRESSION, DELIVERY AND PURIFICATION OF TARGET POLYPEPTIDES 4/21/2015
IPSCIO Record ID: 26281
The Licensee’s liabilities to Licensor were released and terminated; The Licensee’s obligation under the TTA, prior to the Settlement Agreement, to make payments to Licensor in April 2013, November 2013, and April 2014 (the Guaranteed Annual Payments) was terminated and replaced with an obligation to engage Licensor to perform research and development work. Any and all other claims of each party to any other amounts due at June 30, 2013 were mutually released. The Licensee will continue to make royalty payments to the Licensor.
IPSCIO Record ID: 6483
— a world-wide, co-exclusive, with Licensor, research license under Licensor Technology to use ZFP Products in the Field for research purposes and to make and test Licensed Products for research purposes;
— the exclusive right to grant research licenses to Third Parties to use ZFP Products in the Field for research purposes and to make and test Licensed Products for research purposes; and,
— the exclusive right to grant to Sublicensees a license to use ZFP Products in the Field for the sole purpose of generating Licensed Products and, to use, make, offer to sell, sell, and import such Licensed Products.
For Additional Grants to Licensee Effective after Exercise of Option, the following additional licenses and rights under Licensor Technology are
— a world-wide, exclusive license to make, use, and import ZFP Products for use in the Field, which Licensee shall exercise for the sole purposes of generating Licensee Products; or offering for sale and selling ZFP Products at cost to Sublicensees for use in the Field for the sole purpose of generating Licensed Products;
— a world-wide, exclusive license to make, use, sell, offer for sale, and import Licensee Products.
For Non-exclusive rights for Animal Health Products and Human Health Products, each of the licenses and rights granted shall be non-exclusive with respect to Animal Health Products and Human Health Products.
Licensor hereby grants the exclusive right to grant to Sublicensees a license (A) to use ZFP Products in the Field for the sole purpose of generating Licensed Products and (B) to use, make, offer to sell, sell, and import such Licensed Products, all pursuant to Technology Licenses.
Through the initial agreement the Licensee has access to our proprietary zinc finger DNA-binding protein (ZFP) technology and the exclusive right to use ZFP technology to modify the genomes or alter the nucleic acid or protein expression of plant cells, plants, or plant cell cultures. The Licensor has retained rights to use plants or plant-derived products to deliver ZFP transcription factors (ZFP TFsâ„¢) or zinc-finger nuclease (ZFNâ„¢) into human or animals for diagnostic, therapeutic, or prophylactic purposes.
ZFP Product means a zinc-finger protein, including a zinc-finger transcription factor or a zinc-finger nuclease, or a nucleic acid encoding and capable of expressing such protein in a cell or tissue.
Stacking Crop Product means a Crop Product that is a Licensee Product, is the direct or indirect result of using one or more ZFP Products to produce a plant or plant cell comprising Traits, where these Traits were each available in separate plants or plant cells that could have been crossed to produce a breeding stack of the two Traits, and is not the result of any other activity in the Field.
Field means gene targeting and/or gene regulation using a ZFP Product to modify the genome of a plant cell, plant, or plant cell culture (in each case, whether constituting or derived from a vascular or non-vascular plant), or alter the nucleic acid or protein expression in a plant cell, plant, or plant cell culture. For the purpose of this Agreement, non-vascular plants shall include but not be limited to algae, moss, and fungi. Explicitly excluded from the Field are delivery of any ZFP Product into a human or animal for diagnostic, therapeutic or prophylactic purposes, and products intended to result in such delivery.
IPSCIO Record ID: 202855
Licensees Licensed Product means any pharmaceutical formulation or product or method or system which contains an Anti-IgE Antibody.
Licensors Licensed Product means any pharmaceutical formulation or product or method or system which contains an Anti-IgE Antibody identified and synthesized by Licensor and/or a third party, or other IgE inhibiting antibodies within Licensorss MIGIS(R) program.
IPSCIO Record ID: 256278
Licensor grants to Licensee of Germany an exclusive, worldwide, license under the Licensor Licensed Technology to Exploit Licensed Products.
Licensor grants a worldwide, non-exclusive, perpetual, irrevocable and non-terminable license under the Collaboration Patents, as defined in the Collaboration Agreement, with the right to grant and authorize the grant of sublicenses, to Exploit Licensed Products.
GM-CSF Target means the whole or part of the human granulocyte macrophage-colony stimulating factor identified by the SWISS-PROT entry name CSF2 HUMAN and accession number P0414 l.
Single-Chain Antibodies
Antibodies are proteins produced by the body's immune system in response to the presence of antigens, such as bacteria, viruses or other disease causing agents. Antibodies of identical molecular structure that bind to a specific target are called monoclonal antibodies. Single-chain antibodies are genetically engineered antibodies that incorporate only the antigen binding domains of an antibody. Thus, SCAs have the binding specificity and affinity of monoclonal antibodies; however, in their native form they are only one-fifth to one-sixth the size of a monoclonal. The small size of SCAs typically gives them shorter half-lives than monoclonal antibodies, making them better suited for use in acute indications or in other indications where the large size of a monoclonal antibody would inhibit the compound from reaching the area of potential therapeutic activity. In addition, SCAs are a well-established discovery format-of-choice in generating antibodies from phage or yeast display libraries.
The field of use for this agreement otherwise is limited to not include the right to exploit the Products for Radioimmunoguided Surgery(TM), Reagents and kits in the research market for production and cloning of genes encoding Single Chain Antibodies and their fusions in a filamentous bacteriophage-derived vector system, and for expression and screening of Single Chain Antibodies fused with the minor coat protein or attachment or adsorption protein of filamentous bacteriophage, and, Single Chain Antibodies fused with, or for the assay or purification of, Tumor Necrosis l Factor alpha (TNF-a.) or Lymphotoxin.
Products for Radioimmunoguided SurgeryTM (RIGS'), in which a radiolabelled Single Chain Antibody is administered to a cancer patient; time elapses for preferential concentration of the radiolabelled Single Chain Antibody in neoplastic tissue and decrease of background radioactivity in the patient; and such preferentially concentrated radiolabelled Single Chain Antibody is detected within a surgical operative field by a detector probe placed in juxtaposition with tissue suspected of containing said radiolabelled Single Chain Antibody.
IPSCIO Record ID: 121012
Licensees Licensed Product means any pharmaceutical formulation or product or method or system which contains an Anti-IgE Antibody.
Licensors Licensed Product means any pharmaceutical formulation or product or method or system which contains an Anti-IgE Antibody identified and synthesized by Licensor and/or a third party, or other IgE inhibiting antibodies within Licensorss MIGIS(R) program.
IPSCIO Record ID: 204997
– a worldwide, exclusive, to the extent such exclusivity is possible in the light of existing agreements, license to make, have made, use and sell Specialty Canola Products and Specialty High Stearate Canola Products using Licensor Patent Rights, with rights to sublicense,
– a worldwide, non-exclusive license to make, have made, use and sell Commodity Canola Products and Commodity High Stearate Canola Products using Licensor Patent Rights, without the right to sublicense
– a worldwide, non-exclusive license, with no right to sublicense, to make, have made and use, for research purposes only, oilseed products other than Commodity Canola Products, Commodity High Stearate Canola Products, Specialty Canola Products and Specialty High Stearate Canola Products using Licensor Patent Rights, and
– for Specialty Canola Products and Specialty High Stearate Canola Products, the limited right to sublicense only transgenic plant germplasm produced by Licensee, with the right to develop, use and sell new varieties and/or hybrids produced therefrom by traditional plant breeding, containing genes developed or in-licensed by Licensee to any Third Party or Licensee Affiliate.
Agronomic Genes shall mean genes encoding for disease resistance, herbicide tolerance, cold tolerance, shatter resistance, yield improvement, earliness, insect tolerance, drought resistance and heat resistance and other genes that reduce the net unit cost of production of agricultural crop plants.
The patents relate to Increased starch content in Plants and Expression of Sucrose Phosphorylase in Plants.
